Radiation oncology firm Elekta has received clearance for its Flexitron brachytherapy platform from the China Food and Drug Administration (CFDA).
China has a high prevalence of gynecologic cancers, as well as lung, breast, colorectal, and esophageal cancers, Elekta said. There are approximately 130,000 new cervical cancer patients each year in China, and approximately 40,000 Chinese patients are treated with brachytherapy annually, according to the firm.
